Down-regulation of MBD4 contributes to hypomethylation and overexpression of CD70 in CD4+ T cells in systemic lupus erythematosus

Table 1 Patient demographics and medications

Patients	Gender	Age (years)	SLEDAI	Treatment regimen
1	F	25	9	None
2	F	45	10	Pred .20 mg/d HCQ.200 mg/d
3	F	22	10	None
4	F	59	12	Pred .15 mg/d HCQ.200 mg/d TG 30 mg/day
5	F	35	12	Pred .20 mg/d HCQ.200 mg/d
6	F	47	16	Pred .20 mg/d HCQ.200 mg/d TG 30 mg/day
7	F	41	4	Pred .10 mg/d HCQ.200 mg/d
8	M	47	16	Pred .10 mg/d TG 30 mg/day
9	F	23	15	Pred .15 mg/d HCQ.200 mg/d
10	F	47	14	None
11	F	47	6	Pred .15 mg/d HCQ.200 mg/d
12	F	22	15	Pred .40 mg/d HCQ.200 mg/d CTX. 800 mg/once
13	F	38	8	Pred .15 mg/d HCQ.200 mg/d
14	F	17	16	Pred .30 mg/d
15	F	49	5	Pred .7.5 mg/d HCQ.200 mg/d
16	F	19	12	Pred.17.5 mg/d HCQ.200 mg/d
17	F	40	6	Pred .15 mg/d HCQ.200 mg/d
18	M	46	6	Pred .10 mg/d
19	F	17	10	Pred .30 mg/d HCQ.200 mg/d
20	F	54	8	Pred .20 mg/d TG 30 mg/day
21	F	22	18	Pred .40 mg/d HCQ.200 mg/d
				CTX. 800 mg/once
22	F	25	10	Pred .30 mg/d HCQ.200 mg/d
23	F	54	10	Pred .12.5 mg/d HCQ.200 mg/d
24	F	22	6	Pred .5 mg/d HCQ.200 mg/d
25	F	25	10	Pred .15 mg/d HCQ.200 mg

SLEDAI Systemic Lupus Erythematosus Disease Activity Index, F female, M male, Pred prednisone, HCQ hydroxychloroquine, CTX cyclophosphamide, TG tripterygium glycosides, none no treatment with drugs

ISSN: 1868-7083